Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.
Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Johor Bahru 80100, Malaysia.
Nutrients. 2022 Aug 30;14(17):3566. doi: 10.3390/nu14173566.
The ketogenic diet (KD) has been important in treating epilepsy since the 1920s. The benefits of KD further expanded to other neurological diseases, including Alzheimer's diseases, autism spectrum disorder, and nutritional disorder (obesity). Although the therapeutic efficacy of KD has been generally accepted, there is limited knowledge about its underlying mechanism of action, particularly its effect on our gut microbiome. Gut dysbiosis has been proposed to be involved in those diseases, and KD can promote gut microbiota remodeling that may assist in recovery. This review explores the therapeutic applications of KD, the roles of the gut microbiome in neurological diseases and obesity, as well as the effect of KD on the gut microbiome. The present information suggests that KD has significant roles in altering the gut microbiome to improve disease symptoms, mainly by incrementing to (B/F) ratio and reducing in certain cases. However, current gaps call for continued research to understand better the gut microbiota profile altered by KD.
生酮饮食(KD)自 20 世纪 20 年代以来在治疗癫痫方面一直很重要。KD 的益处进一步扩展到其他神经疾病,包括阿尔茨海默病、自闭症谱系障碍和营养障碍(肥胖症)。尽管 KD 的治疗效果已被普遍接受,但对于其作用机制知之甚少,特别是其对我们肠道微生物组的影响。肠道菌群失调被认为与这些疾病有关,KD 可以促进肠道微生物群的重塑,从而有助于恢复。本综述探讨了 KD 的治疗应用、肠道微生物组在神经疾病和肥胖中的作用以及 KD 对肠道微生物组的影响。目前的信息表明,KD 通过增加(B/F)比值和在某些情况下减少来改变肠道微生物组以改善疾病症状方面具有重要作用。然而,目前的差距需要进一步研究来更好地了解 KD 改变的肠道微生物组图谱。